The content on this site is intended for healthcare professionals only
Molecular mechanisms of breast cancer tumours
Published: 12 Jan 2009
Views: 16389
Dr. Kornelia Polyak, Dana-Farber Cancer Institute
Investigating breast cancer tumour evolution and therapeutic resistance
- Categories:
- Breast
- Cell therapy & stem cells
Related Videos
HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan
Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston, US...
11 Sep 2022
Extended adjuvant AI not advised for HPBC after 5+ yrs of sequential endocrine t...
Dr Vivianne Tjan-Heijnen - Maastricht University Medical Center, Maastricht, Net...
11 Sep 2022
Latest updates in treatment for the field of HER2-positive breast cancer
Dr Delia Guaqueta - Memorial Healthcare System, Hollywood, USA
8 Jul 2022
Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast can...
Shanu Modi- Memorial Sloan Ketting Cancer Center, Manhattan, USA
5 Jun 2022
Cancer Services Delivery: Focus on India
Dr Soumitra Datta - Tata Medical Center, Kolkata, India
26 May 2022
The optimal approach after neoadjuvant treatment: The Lucerne toolbox
Prof Maria Cardoso - Champalimaud Foundation, Lisbon, Portugal
3 Feb 2022
OncoAlert and ecancer - ESMO 2021 Day 5
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
21 Sep 2021
OncoAlert and ecancer - ESMO 2021 Day 4
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
20 Sep 2021
6 months trastuzumab non-inferior to 12 months for HER2 positive early breast ca...
Prof Helena Earl - University of Cambridge, Cambridge, United Kingdom
17 Sep 2021